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Hundreds of genes can be regulated by hypoxia-inducible factor 1 (HIF1) under hypoxia. Here we
demonstrated a HIF1-mediated induction of protein phosphatase 1, regulatory subunit 3C gene
(PPP1R3C) in human MCF7 cells under hypoxia. By mutation analysis we conﬁrmed the presence
of a functional hypoxia response element that is located 229 bp upstream from the PPP1R3C gene.
PPP1R3C induction correlates with a signiﬁcant glycogen accumulation in MCF7 cells under hypoxia.
Knockdown of either HIF1a or PPP1R3C attenuated hypoxia-induced glycogen accumulation signif-
icantly. Knockdown of HIF2a reduced hypoxia-induced glycogen accumulation slightly (but not sig-
niﬁcantly). Our results demonstrated that HIF1 promotes glycogen accumulation through regulating
PPP1R3C expression under hypoxia, which revealed a novel metabolic adaptation of cells to hypoxia.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The response to hypoxia is certainly the most well-understood
aspect of hypoxia-inducible factor (HIF)’s ability to regulate metab-
olism [1]. HIF is a heterodimeric protein that is composed of a con-
stitutively expressed beta subunit (HIFb, also called Aryl receptor
nuclear translocator, ARNT) and an O2-regulated alpha subunit
(HIFa) [2,3]. There are three HIFa proteins in higher metazoans.
HIF1a and HIF2a have been the most extensively studied. They
have a similar domain architecture, bind to the same core motif
and also are regulated in a similar manner. HIF3a is an inhibitor
of HIF1 that may be involved in feedback regulation because its
expression is transcriptionally regulated by HIF1 [4]. In well-oxy-
genated cells, HIFa is hydroxylated at one (or both) of two highly
conserved prolyl residues by a family of dioxygenases (EGL nine
homologs, EGLNs, also called prolyl hydroxylase domain proteins,chemical Societies. Published by E
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Zhang).PHDs), which uses O2 and a-ketoglutarate as substrates in a reac-
tion that generates CO2 and succinate as byproducts [5–8]. Pro-
lylhydroxylated HIFa is bound by the von Hippel–Lindau tumor
suppressor protein, which recruits an E3-ubiquitin ligase that tar-
gets HIFa for proteasomal degradation. In addition, a speciﬁc aspa-
raginyl residue in the transactivation domain is hydroxylated in
well-oxygenated cells by factor inhibiting HIF (FIH), which blocks
the binding of the coactivators p300 and CCAAT-binding protein
(CBP) [9–11]. Under hypoxic conditions, hydroxylation is inhibited
and HIFa rapidly accumulates, dimerizes with HIFb, binds to the
core DNA binding sequence 50-RCGTG-30 (R is purine A or G) in tar-
get genes, recruits co-activators and activates transcription.
The hundreds of genes can be induced by HIF1 under hypoxia.
The largest functional group of genes consistently regulated by
HIF1 in a number of cell types are associated with glucose metab-
olism [1]. The glucose metabolism in cells under hypoxia is signif-
icantly different from that under normoxia. Glucose uptake
signiﬁcantly increases under hypoxia, primarily in a HIF-depen-
dent manner. HIF1 induces the transcription of solute carrier fam-
ily 2, member 1 (SLC2A1) and SLC2A3, which encode the glucose
transporter 1 (GLUT1) and GLUT3, respectively [12,13]. HIF1 can
also activate the transcription of hexokinase gene 1 (HK1) and
HK2 [14]. Intracellular glucose is quickly phosphorylated to glu-
cose-6-phosphate by hexokinase. The charged glucose molecule
cannot easily pass back through the plasma membrane and islsevier B.V. All rights reserved.
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metabolic fates, such as, as a structural component in the synthesis
of glycoproteins, metabolized in the pentose shunt to generate ri-
bose, used to synthesize glycogen or, predominantly, broken down
to pyruvate in glycolysis [1].
Although mechanism of regulating glycolysis under hypoxia has
been well deﬁned, the effect of hypoxia on other glucose metabolic
fates is yet to be addressed. Now, some reports have described the
glycogen accumulation in cells under hypoxia conditions [15–18].
Pescador et al. demonstrated that hypoxia promotes glycogen
accumulation through HIF1-mediated induction of glycogen syn-
thase 1 [18]. They also showed that hypoxia upregulates the
expression of UTP: glucose-1-phosphate urydylyltransferase
(UGP2) and 1,4-a glucan branching enzyme (GBE1), in a cell-type
speciﬁc manner [18]. Does hypoxia induce other genes that pro-
mote glycogen accumulation? Some reports showed that protein
phosphatase 1, regulatory subunit 3C (PPP1R3C) could be induced
by hypoxia [19,20], and Ortiz-Barahona et al. predicted that
PPP1R3C is a new HIF-targeted gene [21]. PPP1R3C was also called
protein targeting to glycogen (PTG) and regulated glycogen metab-
olism [22]. Here we demonstrated that hypoxia leads to glycogen
accumulation in human MCF7 cells through HIF1-PPP1R3C path-
way, a new HIF-dependent pathway of glycogen accumulation in
cells under hypoxia conditions.
2. Materials and methods
2.1. Cell culture and hypoxic exposures
MCF7 cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Gibco) supplemented with 10% FBS and 100 units/ml
penicillin, 100 lg/ml streptomycin. Normoxic cells were main-
tained at 37 C in a 5% CO2 and 95% air incubator. The cells were
exposed to hypoxia in three gas incubator (YCP-50S) in 5% CO2,
94% N2 and 1% O2 at 37 C.
2.2. Plasmid constructs
The nucleotide sequences encoding HIF1a-CA5 [23], HIF1a-DN
[23] and HIF2a-DPA [24] were ampliﬁed by PCR and cloned into
FLAG-taged pcDNA6-V5-HisB vector (Invitrogen), respectively.
Promoter region of PPP1R3C were ampliﬁed from human genomic
DNA by PCR and cloned into the luciferase reporter vector pGL3-
promoter (Promega). As a positive control, the nucleotide sequence
containing the identiﬁed hypoxia response element (HRE) of EPO
gene [25] was also cloned into pGL3-promote.
2.3. Western blotting
Cell lysate was subjected to SDS–PAGE and transferred to a
PVDF membrane. Primary antibodies against the following pro-
teins were used: HIF1a (Santa Cruz), HIF2a (Novus Biologicals),
b-actin (Proteintech), and PPP1R3C (Santa Cruz). HRP-conjugated
secondary antibodies were used. Signal was detected using ECL
kit (Millipore).
2.4. Transient transfection and luciferase assay
MCF7 cells were plated into 24-well plates to reach approxi-
mately 40–50% conﬂuence on the next day. The cells were cotrans-
fected with pGL3-promoter-based construct and pRL-TK plasmid
DNAs using Lipofectamine Plus (Invitrogen). The transfection med-
ium was replaced with complete medium after 6 h. The cells were
incubated in normoxia and hypoxia for an additional 24 h. Then
cells were lysed with PLB and reporter gene expression wasassessed using the Dual-Luciferase Reporter Assay System
(Promega).
2.5. RNA isolation and PCR analysis
Cells were dissolved in TRIZOL reagent (Invitrogen) and total
RNA was extracted according to the manufacturer’s instructions.
Total RNA was converted into cDNA using the M-MLV reverse-
transcriptional system (Invitrogen) in the presence of oligo(dT)18.
The cDNA was used for conventional PCR or quantitative real-time
PCR (qrt-PCR) with speciﬁc gene primers: PPP1R3C forward:
50-GCGTTGTGTTTGCTGACTCC, reverse: 50-CGGTTGAAGGCTGAGG-
GAAAT-30; b-actin forward: 50-CTGGCACCACACCTTCTACA-30, reverse:
50-AGCACAGCCTGGATAGCAAC-30; HIF1a forward: 50-AGGTGGATAT
GTCTGGGTTG-30, reverse: 50-AAGGACACATTCTGTTT GTTG-30; HIF2a
forward: 50-GTCTCTCCACCCCATGTCTC-30, reverse: 50-GGTTCTTCAT
CCGTTTCCAC-30. SYBR green PCR mix (Transgen) was used for the
real-time PCR. The relative abundance of PPP1R3C transcript was
quantiﬁed using the comparative Ct method with b-actin as an
internal control.
2.6. Chromatin immunoprecipitation (ChIP)
MCF7 cells were plated into 15 cm plate and grown to about
70% conﬂuence. Then the cells were exposed to hypoxia for 24 h
and ChIP was performed as previous described [18]. The precipi-
tated DNA was ampliﬁed by PCR using the following primers: P1:
50-ACCCGCAGTGACCCACAAAG-30, P2: 50-CGCGGGGAGGTTCTGGG-
ACT-30, P3: 50-TTGAATCTGGCAACCGAGAGG-30, P4: 50-CGAGTCTT
TGGGACATTTGTGC-30. For a positive control, the PDK1 promoter
region that contains a known HIF1-binding site was ampliﬁed
using the forward primer, 50-CGCCCTGTCCTTGAGCC-30 and the re-
verse primer, 50-CGGTATGGAGCGTCCCCT-30 [26].
2.7. Cell transfection with small interference RNA (siRNA)
One day before transfection, MCF7 cells were plated into 6-well
plates. The cells were grown to 50% conﬂuence and then transfec-
ted with 25 nM (ﬁnal concentration) of siGENOME non-targeting
siRNA2, human HIF1A siGENOME SMART pool, or human HIF2A
siGENOME SMART pool, or human PPP1R3C siGENOME SMART
pool (Dharmacon) using Dharma FECT1 transfection reagent
according to the manufacturer’s instructions (Dharmacon). After
24 h incubation at normoxia, the transfection medium was re-
placed with complete medium and then the cells were incubated
at hypoxia for another 24 h. Total RNA and cell lysates were col-
lected for real-time PCR and Western blot, respectively.
2.8. PAS staining and glycogen determination
Coverslips were placed into 6-well plate, then MCF7 cells were
plated. After incubation and treatment, medium was removed and
the cells were ﬁxed with Carnoy’s ﬁxative for 1 h. The cells were
rinsed with absolute alcohol and 66% alcohol once for 2 min, fol-
lowed by rinsing with deionized water for 90 s (3  30 s). The cells
were treated with periodic acid solution for 10 min and then rinsed
with deionized water for 90 s (3  30 s). Then the cells were
treated with Shiff reagent for 15–20 min followed by 5 min with
running tap water. For visualising nuclei, the cells were counter-
stained using Mayer’s hematoxylin for 1 min followed by running
tap water for 5 min. After air-drying, the stained cells were covered
with a glass slides using pure glycerol as mounting medium. For
glycogen determination, glycogen was extracted as previous de-
scribed [27] and the amount of glycogen was assessed by glycogen
assay kit (Biovision).
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Student0s t-test (two-tailed) was performed to analyze Data. P-
values <0.05 were considered signiﬁcant.
3. Results
3.1. Hypoxia induces PPP1R3C expression in an HIF-dependent manner
To examine whether PPP1R3C gene expression is O2-regulated
in human cells, MCF7 cells were incubated at normoxia (21% O2),
hypoxia (1% O2) or medium containing 100 lM deferoxamine mes-
ylate salt (DFOM) for 24 h. Both conventional RT-PCR (Fig. 1A) and
quantitative real-time PCR (qrtPCR; Fig. 1B) assay revealed an in-
creased PPP1R3C mRNA level in the cells under hypoxic or DFOM
treatment conditions. PPP1R3C protein level in the MCF7 cells
was also be determined by immunoblot assay (Fig. 1C). An in-
creased PPP1R3C protein level in company with increased HIF1a
and HIF2a levels was observed in the cells under hypoxic or DFOM
treatment conditions. These results indicated that PPP1R3C was a
hypoxia-inducible gene. In agreement, a signiﬁcantly decreased
PPP1R3C mRNA (Fig. 1D) and protein levels were (Fig. 1E) detected
in the MCF7 cells transfected with siRNAs targeting HIF1a or HIF2a,
which suggested that the inhibition of the HIF genes (especially
HIF1a) reduced hypoxia induction of PPP1R3C. An increased
PPP1R3C mRNA level was also detected in HepG2 cells under hyp-
oxic or DFOM treatment conditions (Supplementary Fig. 1). Taken
together these results demonstrated that PPP1R3C gene could beFig. 1. PPP1R3C is induced by hypoxia in an HIF-dependent manner. (A) PPP1R3C mRNA
hypoxia (H) or medium containing 100 lM deferoxamine mesylate salt (DFOM) for 24 h.
MCF7. The PPP1R3C mRNA level was normalized to b-actin mRNA level. The relative PPP1
levels. (C) HIF1a, HIF2a, PPP1R3C and b-actin protein levels in the MCF7 cells were det
indication of equal protein loading. (D) HIF1a, HIF2a and PPP1R3C mRNA levels were de
were transfected with siRNA of control, HIF1a or HIF2a. After 24 h, the cells were in
transfection experiment was normalized to b-actin mRNA expression. The relative expres
with siHIF1a or siHIF2a over that in the cells transfected with sicontrol. (E) HIF1a, HIF2
cells described in (D). Data shown (B and D) are their mean of three independent experim
repeated twice with similar results. #P > 0.05, §P < 0.05, *P < 0.01.induced in response of cells to hypoxia and this response is regu-
lated by HIF.
3.2. Identiﬁcation and validation of hypoxia-response element
in the human PPP1R3C gene
We searched the promoter region of human PPP1R3C gene for
matches to a consensus HRE sequence as previous described [28].
Four putative HREs (Fig. 2A) were identiﬁed. To determine which
one is a functional HRE, we ampliﬁed the promoter region of
PPP1R3C gene and inserted into luciferase reporter plasmid
pGL3-promoter. As shown in Fig. 2C, the region of 317 to 44
could dramatically increase while the region of 212 to 44 could
not increase luciferase activity in MCF7 cells under hypoxia condi-
tion. In addition, the region of 49 to +249 was also failed to in-
crease luciferase activity in MCF7 cells under hypoxia condition
(Supplementary Fig. 2). Mutation of the putative HRE1 motif com-
pletely impaired the induction of luciferase activity by hypoxia
(Fig. 2C), but mutation of the HRE2 or(and) HRE3 did not impaire
the luciferase activity in MCF7 cells under hypoxia condition (Sup-
plementary Fig. 2), which suggested that HRE1 is a functional HRE.
It has been reported that HIF1a-CA5 and HIF2a-DPA, which en-
code constitutively active form of HIF1a and HIF2a, respectively,
can activate target gene expression under non-hypoxic conditions
[23,24]. As shown in Fig. 2D, cotransfection of the expression vector
encoding HIF1a-CA5 or HIF2a-DPA increased the luciferase activity
of the construct containingHRE1 at normoxia. Mutation of HRE1 re-
sulted in a complete loss of HIF1a-CA5 or HIF2a-DPA-mediatedlevel was analyzed by RT-PCR in MCF7 cells that were cultured under normoxia (N),
(B) PPP1R3C mRNA level was analyzed by quantitative real-time PCR (qrt PCR) in the
R3C mRNA expression was shown as the fold values of hypoxic over normoxic mRNA
ermined by immunoblot assays. Anti-b-actin antibody was used as a control for an
termined by Qrt-PCR in the MCF7 cells transfected with different siRNAs. The cells
cubated at hypoxia for an additional 24 h. The expression of each mRNA in each
sion of each mRNA was shown as the fold values of mRNA levels in cells transfected
a and PPP1R3C protein levels were determined by immunoblot assays in the MCF7
ents. Error bars represent one standard deviation. The experiments (A, C, and E) were
Fig. 2. Identiﬁcation and validation of HREs in the PPP1R3C gene. (A) Skech map of PPP1R3C promoter region. The putative HREs are pointed out by the arrows. The
nucleotides of HRE1 and ﬂanking sequences were shown and HRE1 was mutated as indicated (red). The nucleotide sequences are numbered in relation to the transcription
initiation site, which is designated ‘‘+1”. P1, P2, P3 and P4 indicated primers that are used for PCR ampliﬁcation of the immunoprecipitated chromatin fragments in Fig. 2F.
(B) Comparison of the hypoxia response element (red) and ﬂanking nucleotides identiﬁed in the human, rat and mouse PPP1R3C gene promoter regions. (C) Luciferase
reporter assays were performed in MCF7 cells transfected with the constructs containing the indicated sequences from the human PPP1R3C gene promoter region. Each
transfection experiment was performed triplicate. The relative mean luciferase activity in the cells under hypoxia is shown as fold over the mean activity in the cells under
normoxia. Error bars represent one standard deviation. ‘‘HRE1 mut” contains the promoter region of PPP1R3C from 317 to 44 with the HRE1 mutation as indicated in
Fig. 2A. (D) Reporter plasmids were co-transfected into MCF7 cells along with pcDNA6V5HisB empty vector plasmid (EV), pcDNA6V5 HisB-HIF1a-CA5 or HIF2a-DPA
expression plasmid. Mean luciferase activity of three independent experiments is shown relative to activity in the cells transfected with empty vector and incubated at
normoxia. Error bars represent one standard deviation. E. Reporter plasmids were co-transfected into MCF7 cells along with a pcDNA6V5HisB empty plasmid (EV) or HIF1a-
DN expression plasmid that encodes a dominant-negative form of HIF1a, and were incubated at normoxia or hypoxia for 24 h. Mean luciferase activity of three independent
experiments is shown as fold relative to the activity in the cells transfected with empty vector pcDNA6V5HisB and incubated at normoxia. Error bars represent one standard
deviation. (F) ChIP-PCR assays were performed using the indicated primers and antibodies to demonstrate binding of HIF1a to HRE1 of PPP1R3C in the MCF7 cells under
normoxia and hypoxia. H and N represent hypoxia and normaxia, respectively.
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contribute to increased PPP1R3C promoter activity in hypoxic cells.
To further test this, MCF7 cells were cotransfected with pcDNA6V5-
HisB-HIF1a-DN, which encodes a dominant-negative form of HIF1a
that competes with endogenous HIF1a and HIF2a for dimerization
with HIF1b and thus abolishes trans-activation effect of the hetero-
dimers [23]. As expected HIF1a-DN inhibited hypoxia-induced
PPP1R3C promoter activity in MCF7 cells (Fig. 2E) and HeLa cells
(Supplementary Fig. 3).
To demonstrate that HIF1a binds to the HRE1 within living
cells, we performed chromatin immunoprecipitation (ChIP) assays
using hypoxia-treated MCF7 cells and HIF1a antibodies (using IgG
as a negative control). The amplicon containing the HRE1 of thePPP1R3C gene was detected from chromatin fragments immuno-
precipitated with HIF1a (Fig. 2F). For a positive control, we demon-
strated binding of HIF1 to a known HIF1 target gene PDK1 [26]. For
a negative control, amplicon with HRE4 of the PPP1R3C gene was
detected.
Taken together, these results showed that PPP1R3C is induced
by HIF10 combining to the HRE1 in MCF7 cells under hypoxia.
3.3. Hypoxia induces glycogen accumulation in MCF7 cells
PPP1R3C is also known as PTG. By overexpression studies and
transgenic animal models PPP1R3C has been shown to potently
regulate glycogen levels [29–37]. In order to test the functional
4370 G.-M. Shen et al. / FEBS Letters 584 (2010) 4366–4372relevance of increased glycogen levels, MCF7 cells were exposed to
hypoxia or normoxia and their glycogen levels were determined at
different time points. Both PAS staining (Fig. 3A) and glycogen
quantity determination (Fig. 3B) explored a signiﬁcant increase of
cellular glycogen concentration under hypoxia conditions. These
results conﬁrmed that the hypoxic induction of PPP1R3C correlates
with the increase in glycogen reserves in MCF7 cells.
3.4. Hypoxia-induced glycogen accumulation is HIF-dependent in
MCF7 cells
To test the role of HIF in hypoxia-induced glycogen accumula-
tion, MCF7 cells were transfected with small interference RNAs
(siRNAs). The cell transfection with siRNA that speciﬁcally target
HIF1a (siHIF1a) signiﬁcantly attenuated the hypoxia-induced
glycogen accumulation (Fig. 4A and B). The cell *transfection with
siRNA that speciﬁcally target HIF2a (siHIF2a) attenuated the
hypoxia-induced glycogen accumulation slightly (Fig. 4A and B).
These results demonstrated that HIF1a is necessary for the hypoxia-
induced glycogen accumulation.
3.5. PPP1R3C mediates the hypoxic accumulation of glycogen
To further test the role of PPP1R3C in hypoxia-induced glyco-
gen accumulation, we transfected MCF7 cells with siRNAs. In
comparison with the cells transfected with non-targeting siRNAFig. 3. Hypoxia induces glycogen accumulation in MCF7 cells. (A) PAS staining of
the cells that were exposed to normoxia or hypoxia for different times. (a) at
normoxia for 24 h; (b) at hypoxia for 24 h; (c) at normoxia for 48 h; (d) at hypoxia
for 48 h. The experiment was repeated twice with similar results. (B) Glycogen
content determination in the cells that were exposed to normoxia or hypoxia for the
point times. Data shown are their mean of three independent experiments and
error bars represent one standard deviation. *P < 0.01.(sicontrol), a signiﬁcant reduction of glycogen accumulation
(Fig. 5A and B), accompanying a reduction of both PPP1R3C
mRNA and protein levels (Fig. 5C and D), was observed in the
cells transfected with the siRNA that speciﬁcally targets to
PPP1R3C (siPPP1R3C). These results suggested a signiﬁcant effect
of PPP1R3C on the hypoxia-induced glycogen accumulation.4. Discussion
In this study we demonstrated that PPP1R3C was regulated by
HIF under hypoxia and hypoxia promotes glycogen accumulation
through HIF-mediated induction of PPP1R3C in MCF7 cells. HIF1a
should play a main role in this process. Although dual-luciferase
reporter assays showed that PPP1R3C promoter is induced by
HIF2a (Fig. 2D), the siRNA that especially targets HIF2a mRNA (si-
HIF2a) did not reduced PPP1R3CmRNA level (Fig. 1D) signiﬁcantly.
In addition, the siRNA that especially targets HIF1a mRNA (siHI-
F1a) rather than siHIF2a can reduce glycogen accumulation signif-
icantly (Fig. 4B). So the PPP1R3C’s induction by hypoxia is mainly
attributed to HIF1a, and PPP1R3C may be a selective target gene
of HIF1a. Pescador’s results indicated that hypoxia induced a coor-
dinated response that affects glycogen metabolism at multiple lev-
els. Our results supported these.
Ortiz-Barahona and colleagues used a computational strategy
based on the combination of phylogenetic footprinting and tran-
scription proﬁling meta-analysis for a genome-wide identiﬁcation
of HIF binding sites and target genes, and identiﬁed a potential HRE
that is from 14 to 10 in the PPP1R3C promoter [21]. In this
study we conﬁrmed a functional HRE that is from 230 to 226
in the PPP1R3C promoter using report gene assay and ChIP-PCR
analysis. The discrepancy on the HRE identity may be caused by
the difference in deﬁning the conditions of HIF-binding sites
(HBSs).
It was reported that PTG regulates glycogen metabolism
through directly binding to protein phosphatase 1 (PP1). Theoreti-
cally, PTG-PP1 complex could act via regulation of glycogen syn-
thase, glycogen phosphorylase, or both enzymes [37]. Cynthia
et al. reported PTG-PP1 complex resulted in cellular glycogen accu-
mulation through regulating glycogen phosphorylase but not gly-
cogen synthase [37]. Other reports also supported this [30,32,38].
Pescador et al. demonstrated that under hypoxia, the increased
GS activity is a consequence of the incremented amount of en-
zyme, rather than of a shift in its activation state. They also found
reduction of glycogen phosphorylase (GP) activity in cells exposed
to hypoxia [18]. Reduction of GP activity was also observed during
prolonged hypoxia [16]. So we hypothesize that under hypoxia
PPP1R3C interacts with PP1 dephosphorylates GP and reduces GP
activity, thus repressing glycogen breakdown.
Glycogen accumulation maybe involves in longterm adaptation
to hypoxia. Exposure of cells to hypoxia, prior to the anoxic treat-
ment in the absence of glucose, resulted in increased survival [18].
O2 concentrations are signiﬁcantly reduced in many human tumors
compared with the surrounding normal tissue. Reduced O2 medi-
ates adaptive responses of tumor cell to changes in tissue oxygen-
ation [39]. Glycogen accumulation in some cancers had been
reported [40–49]. Glycogen accumulation in cancer maybe in-
volves in adaptation to tumor microenvironment Exposure of cells
to hypoxia, prior to the anoxic treatment in the absence of glucose,
resulted in increased survival [18]. Further work is required to test
whether glycogen accumulation exists in tumors widely and
PPP1R3C plays a role in the process.
In summary, our results demonstrated that HIF1 promotes gly-
cogen accumulation through regulating PPP1R3C expression under
hypoxia, which revealed a novel metabolic adaptation of cells to
hypoxia.
Fig. 4. Glycogen accumulation is attenuated by knockdown of HIF1a or HIF2a. MCF7 cells were transfected with siRNA of control, HIF1a or HIF2a for 24 h, then incubated at
hypoxia for an additional 24 h. (A) PAS staining of cells. The experiment was repeated twice with similar results. (B) Glycogen content determination of cells. Data shown are
their mean of three independent experiments and error bars represent one standard deviation. #P > 0.05, *P < 0.01.
Fig. 5. Glycogen accumulation is attenuated by knockdown of PPP1R3C. MCF7 cells
were transfected with siRNA of control and PPP1R3C for 24 h, then incubated at
hypoxia for an additional 24 h. (A) PAS staining of cells. The experiment was
repeated twice with similar results. (B) Glycogen content determination of cells.
Data shown are their mean of three independent experiments and error bars
represent one standard deviation. (C) PPP1R3C, HIF1a and HIF2amRNA levels were
determined by qrtPCR. The PPP1R3C, HIF1a and HIF2a mRNA levels were
normalized to b-actin mRNA levels. The relative expression of each mRNA was
shown as the fold values of mRNA levels in cells transfected with siPPP1R3C over
that in the cells transfected with sicontrol. Data shown are their mean of three
independent experiments and error bars represent one standard deviation.
*P < 0.01. (D) PPP1R3C, HIF1a, HIF2a and b-actin protein levels were determined
by immunoblot assays. Anti-b-actin antibody was used as a control for an indication
of equal protein loading. The experiment was repeated twice with similar results.
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